ライフサイエンスコーパス: exudative

1 +/- 8.8 years) with nonexudative (54.2%) and exudative (45.8%) AMD to measure retinal vessel density

2 hemorrhage on DFE or fundus photography and exudative activity on SD OCT.

3 hotography at 3 months and no evidence of SD-exudative activity requiring retreatment at month 3.

4 After baseline, exudative activity was detected on SD-OCT in more than 8

5 However, OCT may not always detect exudative activity.

6 MA) in consecutive naive eyes diagnosed with exudative age-related macular degeneration (AMD) in comp

7 a 27-year-old control, 1 from a 78-year-old exudative age-related macular degeneration (AMD) patient

8 Anastomotic vessels in exudative age-related macular degeneration (AMD) represe

9 f this pathway, are altered in patients with exudative age-related macular degeneration (AMD).

10 with focal vitreomacular adhesion (VMA) and exudative age-related macular degeneration (AMD).

11 ibutor to the development and progression of exudative age-related macular degeneration (AMD).

12 s complex surgery used to restore reading in exudative age-related macular degeneration (AMD).

13 of having or confirmed to have glaucoma and exudative age-related macular degeneration (AMD).

14 IMPORTANCE Exudative age-related macular degeneration (ARMD) is the

15 rget SRH may augment anti-VEGF treatments in exudative age-related macular degeneration and other dis

16 horoidal neovascularization in patients with exudative age-related macular degeneration and suggested

17 ved intravitreous bevacizumab injections for exudative age-related macular degeneration between Janua

18 Compared to exudative age-related macular degeneration fewer injecti

19 othelial growth factor (VEGF) injections for exudative age-related macular degeneration or macular ed

20 ses to deliver excellent visual outcomes for exudative age-related macular degeneration patients whil

21 ul analysis of randomized clinical trials on exudative age-related macular degeneration reveals appar

22 irty-seven B-scan images of 37 patients with exudative age-related macular degeneration were chosen r

23 Patients were enrolled with unilateral exudative age-related macular degeneration who had recei

24 ncluding proliferative diabetic retinopathy, exudative age-related macular degeneration, and retinopa

25 taract and macular edema secondary to either exudative age-related macular degeneration, diabetic mac

26 tiation of intensive ranibizumab therapy for exudative age-related macular degeneration, macular atro

27 the use of aflibercept for the treatment of exudative age-related macular degeneration.

28 oses of maculopathy in patients with IC were exudative AMD (1.5%), drusen (0.8%), nonexudative AMD (0

29 ociated with an increased hazard of incident exudative AMD (HR, 1.71; 95% CI, 1.04-2.82), but not pur

30 IMT, 1.31; CI, 1.05-1.64; P = 0.02) but not exudative AMD (OR per 0.1 mm IMT, 1.14; CI, 0.97-1.34; P

31 ssion to GA (OR 1.14; 95% CI, 1.07-1.21) and exudative AMD (OR, 1.08; 95% CI, 1.01-1.14).

32 ting for age, female sex was associated with exudative AMD (OR, 2.10; 95% CI, 1.10-3.98) and plasma H

33 Exudative AMD (wet AMD) is treated by monthly injection

34 ding 89 consecutive patients with unilateral exudative AMD and >/=3 years of followup.

35 ide association study on 2,119 patients with exudative AMD and 5,691 controls, with independent repli

36 tion was conducted to identify patients with exudative AMD and choroidal neovascularization (CNV) in

37 Patients with a diagnosis of unilateral exudative AMD and confirmed to have or suspected of havi

38 adults with no AMD, early AMD, and late AMD (exudative AMD and pure geographic atrophy) were 618.8 (1

39 sly showed the macular fluid associated with exudative AMD and the ability of anti-VEGF therapy to re

40 e rates were calculated for nonexudative and exudative AMD and were stratified by Asian ethnicity.

41 use the Icon binds selectively to the CNV in exudative AMD as well as to laser-induced CNV, the Icon

42 In patients with bilateral exudative AMD at baseline, final vision at year 7 was si

43 a 5-year follow-up period were identified in exudative AMD beneficiaries newly diagnosed in 2006, the

44 ons of bevacizumab as the sole treatment for exudative AMD between September 2008 and October 2014 (n

45 Retinal VD is decreased in eyes with exudative AMD compared with nonexudative AMD but is unaf

46 Eyes with exudative AMD demonstrated lower VD, especially in the p

47 those, there were 540 with and 4453 without exudative AMD diagnoses.

48 more effective therapeutic interventions for exudative AMD diffused rapidly throughout the United Sta

49 ssions were used to compare nonexudative and exudative AMD eyes and the impact of anti-vascular endot

50 ng with the significantly thicker choroid in exudative AMD eyes before treatment initiation compared

51 The incidence of RVMA in exudative AMD eyes was significantly lower compared with

52 Exudative AMD eyes were separated into 2 groups: anti-VE

53 idal thickness was 172.1 +/- 60.0 mum in non-exudative AMD eyes, 196.4 +/- 89.8 mum in exudative AMD

54 on-exudative AMD eyes, 196.4 +/- 89.8 mum in exudative AMD eyes, and 207.4 +/- 77.7 mum in control ey

55 exudation within a future time-frame in non-exudative AMD eyes.

56 were no significant differences in risk for exudative AMD for any of the Asian ethnicities compared

57 elative risk for developing nonexudative and exudative AMD for persons of different Asian ethnicities

58 Fellow eyes with exudative AMD had received a mean 7.3 total injections o

59 ion of anti-VEGF agents in 2006 for treating exudative AMD has not posed a threat of increased risk o

60 the use of bevacizumab for the treatment of exudative AMD has saved Medicare over $40 billion since

61 nt group; beneficiaries newly diagnosed with exudative AMD in 2000 or nonexudative AMD in 2000 or 200

62 Beneficiaries with a first diagnosis of exudative AMD in 2006 were the treatment group; benefici

63 For the 35% of subjects with exudative AMD in both eyes at baseline, within-patient c

64 aser-induced CNV in a mouse model simulating exudative AMD in humans.

65 23 subjects, including 15 patients with non-exudative AMD in one eye and exudative AMD in the fellow

66 tients with non-exudative AMD in one eye and exudative AMD in the fellow eye, and 8 age-matched contr

67 real aflibercept injection (IAI) therapy for exudative AMD including both typical neovascular AMD and

68 total of 23 941 Medicare beneficiaries with exudative AMD newly diagnosed during 1992-2009.

69 total of 23 941 Medicare beneficiaries with exudative AMD newly diagnosed during 1992-2009.

70 t this late stage in the therapeutic course, exudative AMD patients remain at risk for substantial vi

71 Among exudative AMD patients with glaucoma or suspected of hav

72 We found that DKK-1 levels were decreased in exudative AMD patients, compared with healthy controls (

73 For discriminating exudative AMD patients, the optimum diagnostic cutoff of

74 the fellow eyes of patients with unilateral exudative AMD ranged from 6.25% to 27%.

75 dosing of anti-VEGF therapy in patients with exudative AMD results in favorable long-term preservatio

76 surements between eyes with nonexudative and exudative AMD using optical coherence tomography angiogr

77 le dementia was 1.35 (95% CI, 0.89-2.06) for exudative AMD versus the controls and 1.44 (95% CI, 1.26

78 The odds ratio (OR) of exudative AMD was 11.71 (95% CI; 5.24-6.13) for lowest v

79 eficiaries treated with anti-VEGF agents for exudative AMD was considerably greater than for prior in

80 Exudative AMD was diagnosed in 253 eyes of 221 patients.

81 New-onset investigator-determined exudative AMD was reported more frequently in pegcetacop

82 ive patients with unilateral treatment-naive exudative AMD were entered into the study over 6 months.

83 grated health care setting, 59 patients with exudative AMD were identified who were able to be effect

84 patients presenting with blurred vision and exudative AMD were imaged before and after anti-VEGF tre

85 A total of 234 patients with exudative AMD were initially treated with 3 monthly IAI

86 This study examined all patients with exudative AMD who were receiving intravitreal anti-VEGF

87 We included 185 eyes of 141 patients with exudative AMD who were scheduled for their first treatme

88 11.0% pure geographic atrophy [GA] and 11.7% exudative AMD).

89 VMA (RVMA) was found in 15 (15.3%) eyes with exudative AMD, 21 (28.0%) eyes with nonexudative AMD, an

90 In patients with unilateral exudative AMD, 3 years of oral DHA-enriched supplementat

91 Plasma was obtained from 128 patients with exudative AMD, 46 patients with atrophic AMD and 111 hea

92 VMA was present in 101 (25.1%) eyes with exudative AMD, 84 (24.0%) eyes with nonexudative AMD, an

93 dual, 1 patient with dry AMD, 1 patient with exudative AMD, and 1 patient with nonproliferative diabe

94 ociated with the development and severity of exudative AMD, and have potential to become a biomarker

95 thy is more prevalent in Asian patients with exudative AMD, but is more prevalent than generally reco

96 sociated severe vision loss cases are due to exudative AMD, characterized by neovascularization.

97 tive age-related macular degeneration (AMD), exudative AMD, hereditary maculopathy, and toxic maculop

98 anibizumab was approved for the treatment of exudative AMD, intravenous bevacizumab was approved to t

99 Unlike clinical trials for exudative AMD, it is impractical to use the change in vi

100 re geographic atrophy (GA), it was 0.6%; for exudative AMD, it was 0.9%; and for progression of AMD,

101 eloping a preclinical model that phenocopies exudative AMD, our studies revealed that the photorecept

102 In eyes with exudative AMD, previous anti-VEGF treatments did not imp

103 affected by the presence of non-exudative or exudative AMD, providing insight into changes in vessel

104 e and diagnosis of drusen, nonexudative AMD, exudative AMD, toxic maculopathy, hereditary dystrophy,

105 f the fellow eye of patients with unilateral exudative AMD, using a novel semiautomated grading syste

106 investigate the causes and histopathology of exudative AMD, we conditionally induced hypoxia in a nov

107 ta were collected on all eyes diagnosed with exudative AMD, which included ethnic data.

108 RVMA over time was found in eyes affected by exudative AMD.

109 and have potential to become a biomarker for exudative AMD.

110 ith a 71% increase in the hazard of incident exudative AMD.

111 s a qualitative criterion for retreatment of exudative AMD.

112 or treatment using proton beam radiation for exudative AMD.

113 uccess with VEGF inhibitors in patients with exudative AMD.

114 an important trigger for the progression of exudative AMD.

115 anti-VEGF treatment success in patients with exudative AMD.

116 >50 years and had angiographically verified exudative AMD.

117 4%) had nonexudative AMD and 217 (0.49%) had exudative AMD.

118 to identify enrollees with nonexudative and exudative AMD.

119 choroidal neovascularization, a hallmark of exudative AMD.

120 so be efficacious for treating patients with exudative AMD.

121 tients who are at high risk of conversion to exudative AMD.

122 d, 533 eyes of 429 patients were treated for exudative AMD.

123 l neovascularization, a hallmark of advanced exudative AMD.

124 intravenous bevacizumab for the treatment of exudative AMD.

125 ation; SD] age 77.8 [8.0] years) affected by exudative AMD; 350 eyes of 298 subjects (mean [SD] age 7

126 n, the CFH variant appears to play a role in exudative and atrophic disease, whereas the ELOVL4 varia

127 ter number of INL cystoid spaces in both the exudative and FTMH subgroups (P = .001).

128 ts in stabilization of vision, resolution of exudative and hemorrhagic complications with regression

129 tases, abnormal choroidal vascular networks, exudative and hemorrhagic presentation) with polypoidal

130 The peripheral mass lesions were highly exudative and hemorrhagic, and usually associated with a

131 tinal community has prevented blindness from exudative and neovascular ocular diseases worldwide whil

132 esults indicate that the development of both exudative and nonexudative AMD is associated with distin

133 normal subjects and patients with untreated exudative and nonexudative AMD.

134 de spectrum of clinical phenotypes including exudative and nonexudative maculopathy was observed, wit

135 te retinal necrosis (ARN), which can lead to exudative and rhegmatogenous retinal detachment, yet lit

136 showed OCT, OCT-A, and BFAF features of both exudative and tractional cystoid spaces, but without any

137 Exudative and tractional intraretinal cystoid spaces dis

138 e mesangioproliferative, acute proliferative/exudative, and crescentic GN.

139 osis are (1) presence of erythematous-scaly, exudative, and crusted lesions involving >/=3 areas, inc

140 The treatment and management of exudative ARMD are changing dramatically.

141 68 years or older newly diagnosed as having exudative ARMD as indicated by beneficiaries having no c

142 erapy for patients 68 years or older with an exudative ARMD diagnosis in community-based settings in

143 T&E treatment protocol with ranibizumab for exudative ARMD in a 24-month period and suggests that su

144 ts of introducing new therapies for treating exudative ARMD on vision of the affected population and

145 ween beneficiaries newly diagnosed as having exudative ARMD who received photodynamic therapy or anti

146 ment efficiencies in patients suffering from exudative ARMD with a BCVA </= 0.05.

147 mong beneficiaries newly diagnosed as having exudative ARMD, the introduction of anti-VEGF therapy re

148 cted treatment naive patients diagnosed with exudative ARMD.

149 We found that lgtA in exudative bacteria is IF and that lgtC is OOF.

150 ce succumbed to a purulent multifocal severe exudative bronchopneumonia that closely resembles the di

151 ally to identify intraretinal and subretinal exudative cells.

152 degeneration presenting with hemorrhagic and exudative changes within the macula and/or peripapillary

153 ent CNV (n=7), RPE atrophy with a history of exudative CNV (n=10), and RPE atrophy without evidence o

154 ted by OCTA in the fellow eyes of those with exudative CNV.

155 nd of year 2 that was not related to loss of exudative control.

156 sion syndrome is a rare entity of idiopathic exudative detachments of uveal tissues and retina.

157 ost TREX patients who demonstrated recurrent exudative disease activity (17/24 [71%]) were unable to

158 ain optical coherence tomography evidence of exudative disease activity; the interval between visits

159 he ELOVL4 variant may play a greater role in exudative disease in our population.

160 Active exudative disease was detected by spectral-domain OCT in

161 ed a grade ranging from 1 (no disease) to 5 (exudative disease).

162 diagnosed advanced AMD (geographic atrophy, exudative disease, or AMD causing visual loss) in one or

163 ve MNV seems to be an important predictor of exudative disease.

164 n lesion size enlargement is the duration of exudative disease.

165 ry received prompt treatment; 6 eyes without exudative features at study entry received deferred trea

166 Twenty-four eyes with exudative features at study entry received prompt treatm

167 study entry, gray lesion was associated with exudative features in 24 of 30 eyes (80%), including sub

168 Exudative features of myopic CNV are more obvious on FA

169 CNV was associated with exudative features on fluorescein angiography in 82% of

170 During fixed dosing (weeks 12-52) all exudative features showed synchronized fluctuations afte

171 With therapeutic intervention, exudative features such as IRC and SRF resolved rapidly

172 Exudative fellow eyes remained at risk for further visio

173 rea surrounding this cyst showed significant exudative fluid collection with diffuse, floating echoes

174 ysis, 4 (5%) eyes had complete resolution of exudative fluid, 40 (49%) showed partial resolution, 26

175 ined unchanged, and 12 (14%) showed worsened exudative fluid.

176 uman ascites fluid in vitro, an inflammatory exudative fluid.

177 , demonstrating a clear association with the exudative form of disease, thereby creating the possibil

178 ase and current treatment modalities for the exudative form of the disease require repeated intravitr

179 Peripheral exudative hemorrhagic chorioretinopathy shares many char

180 melanoma include choroidal nevus, peripheral exudative hemorrhagic chorioretinopathy, congenital hype

181 ies of 40 patients (48 eyes) with peripheral exudative hemorrhagic chorioretinopathy.

182 Effusions were exudative in 78% of the assessable cases.

183 Exudative intraretinal cystoid spaces (36/72 eyes, 50%)

184 ignificant predictors for the development of exudative late-stage AMD (P > 0.05).

185 an influx of airway neutrophils and CD11b(+) exudative macrophages, which was reduced in TLR2(-/-) mi

186 l pigment abnormalities (26.6% versus 7.3%), exudative macular degeneration (5.2% versus 0.1%), and g

187 y, threshold retinopathy of prematurity, and exudative macular degeneration appear to be especially c

188 18 years of age or older with a diagnosis of exudative macular degeneration or diabetic macular edema

189 up examination of pure geographic atrophy or exudative macular degeneration, any type of drusen with

190 he following: (1) laser photocoagulation for exudative macular degeneration; (2) laser treatment for

191 etinal fluid types across the most prevalent exudative macular diseases and OCT devices.

192 SLG were observed in several other exudative macular diseases.

193 reflective intraretinal fluid across various exudative maculopathies.

194 corresponded to regions of SSPiM in several exudative maculopathies.

195 Eyes with various forms of exudative maculopathy including diabetic retinopathy (DR

196 ix eyes in 62 patients with various forms of exudative maculopathy were evaluated; 60 eyes with DR, 9

197 ortant to recognize that adequately treating exudative MNV remains the best option to optimize vision

198 with the other 393 eyes in which subsequent exudative nAMD did not develop (0.28 mm/year; 95% CI, 0.

199 with the other 684 eyes in which subsequent exudative nAMD did not develop (0.29 mm/year; 95% CI, 0.

200 aluated for (1) GA presence and area and (2) exudative nAMD presence.

201 GA, GA enlargement before the development of exudative nAMD seems slowed.

202 ing to the presence or absence of subsequent exudative nAMD.

203 ars), 73 eyes (9.6%) demonstrated subsequent exudative nAMD.

204 rs), 63 eyes (13.8%) demonstrated subsequent exudative nAMD.

205 seems to be a precursor for the formation of exudative neovascular AMD, there is evidence suggesting

206 te sequelae such as outer retinal atrophy or exudative neovascular membranes develop, which could pro

207 Since exudative neutrophils of wild-type mice expressed little

208 , but is not affected by the presence of non-exudative or exudative AMD, providing insight into chang

209 ovascular AMD" should be preceded by either "exudative" or "nonexudative" when describing this neovas

210 The exudative, or the wet form of age-related macular degene

211 bling the vitelliform lesions found in acute exudative paraneoplastic polymorphous vitelliform maculo

212 ke RP is distinct from Coats disease in that exudative pathologic features occur exclusively in the s

213 The exudative phase would manifest as ground-glass opacities

214 In its early exudative phase, neutrophil activation and accumulation

215 se paracrine mediators to the angiogenic and exudative phenotype of KS lesions remains unclear.

216 HU values can help in differentiating exudative pleural effusions from transudative pleural ef

217 ibe clinical findings in patients with acute exudative polymorphous vitelliform maculopathy (AEPVM).

218 Acute exudative polymorphous vitelliform maculopathy can prese

219 mpletely discriminate between pale, soft and exudative (PSE) and pale-only muscles.

220 in oxidation and the onset of pale, soft and exudative (PSE) condition in chicken breast are studied.

221 rbling score, rare occurrence of pale, soft, exudative (PSE) meat, but low growth rate and carcass we

222 which are strikingly similar to pale, soft, exudative (PSE) pork.

223 wing to the presence of ERM (10 eyes), large exudative RD (4 eyes), or vitreous hemorrhage (1 eye).

224 globe injury (n = 5), 1 patient demonstrated exudative RD and 1 patient demonstrated retinal dialysis

225 1 (10%) achieved resolution with monitoring (exudative RD); 1 (10%) underwent cryopexy and pneumatic

226 gnificantly increased for rhegmatogenous and exudative RD, with adjusted odds ratios of 1.41 (95% CI,

227 ected by posterior uveal melanoma with large exudative retinal detachment (>10 mm in largest basal di

228 ected by posterior uveal melanoma with large exudative retinal detachment (>10 mm in largest basal di

229 r sheathing (aHR, 2.6, 95% CI, 1.4-4.9), and exudative retinal detachment (aHR, 4.1, 95% CI, 1.3-13).

230 tudy evaluated the risk and risk factors for exudative retinal detachment (ERD) in ocular inflammator

231 Exudative retinal detachment (ERD) localized to the infr

232 ictive of poor final VA included presence of exudative retinal detachment (P = 0.004), baseline VA 20

233 d tumor thickness (P = 0.03) and presence of exudative retinal detachment (P = 0.01) were predictive

234 hickness and largest basal diameter, largest exudative retinal detachment basal diameter, tumor locat

235 Drainage of exudative retinal detachment may be necessary for either

236 Marked exudative retinal detachment regression was documented i

237 Exudative retinal detachment resolution (B-scan ultrason

238 main outcome measure: Exudative retinal detachment resolution (B-scan ultrason

239 etonide injection induces earlier and marked exudative retinal detachment resolution after brachyther

240 e present a 13-year-old girl with macula-off exudative retinal detachment secondary to Vogt-Koyanagi-

241 ensive investigations for possible causes of exudative retinal detachment were performed with unremar

242 chnique for non-resolving vision-threatening exudative retinal detachment which combines the advantag

243 reater tumor thickness, vitreous hemorrhage, exudative retinal detachment, and poor baseline VA predi

244 Band keratopathy, >/= 3+ vitreous cells, exudative retinal detachment, posterior synechia, and a

245 rome with characteristic findings, including exudative retinal detachment, rapid cataract formation,

246 closure glaucoma, cystic macular edema, and exudative retinal detachment.

247 >grade 0; cataract; macular thickening; and exudative retinal detachment.

248 to progression to bilateral panuveitis with exudative retinal detachment.

249 Both patients had exudative retinal detachments (ERD).

250 rom dermal and retinal vessels and prevented exudative retinal detachments in double-transgenic mice

251 ncluded patients presenting with symptomatic exudative retinal papillary capillary hemangioma with or

252 n develop in patients with NF1 and can cause exudative retinopathy, vitreous hemorrhage, and visual l

253 ed from the lymphatic drainage also known as exudative seroma (ES) of stage III melanoma patients obt

254 treatment (after 1 month observation), when exudative signs emerged (SRF in 3/6 eyes and retinal cys

255 treated patients with wet AMD, who showed no exudative signs on the day of blood drawing had a cytoki

256 ll consenting patients with chronic moist or exudative skin ulcers.

257 nePVAC may represent the subclinical pre-exudative stage of ePVAC, notable for an absence of exud

258 haracterised by a pale colour and grainy and exudative texture.

259 Patients usually present with an exudative tonsillitis, sore throat, dysphagia, and unila

260 lusion criteria included RRD before 2009 and exudative, tractional, or traumatic retinal detachments.

261 on in areas co-localizing with quiescent and exudative type 1 CNV.

262 0.46 (95% CI, 0.41-0.51) in the presence of exudative type 1 CNV.

263 isk for RD, including the rhegmatogenous and exudative types.

264 All consenting patients with atraumatic exudative ulcers of >1 cm diameter were enrolled.

265 Neisseria gonorrhoeae causes severe exudative urethritis.

266 e uncommon entity, referred to as perifoveal exudative vascular anomalous complex (PEVAC) by describi

267 Coats-like exudative vasculopathy, not previously reported in JNCL,

268 elated vitreoretinopathies, such as familial exudative vitreoretinopathies including Norrie disease.

269 in vivo microstructural features of familial exudative vitreoretinopathy (FEVR) have not been well de

270 associated with autosomal dominant familial exudative vitreoretinopathy (FEVR) in families linking t

271 ating some pathological features of familial exudative vitreoretinopathy (FEVR) in human patients.

272 Familial exudative vitreoretinopathy (FEVR) is a genetically hete

273 Familial exudative vitreoretinopathy (FEVR) is a hereditary eye d

274 Familial exudative vitreoretinopathy (FEVR) is a human disease ch

275 Familial exudative vitreoretinopathy (FEVR) is a rare finding in

276 Familial exudative vitreoretinopathy (FEVR) is an inherited blind

277 Familial exudative vitreoretinopathy (FEVR) is an inherited blind

278 Familial exudative vitreoretinopathy (FEVR) is characterized by d

279 l retina, typically associated with familial exudative vitreoretinopathy (FEVR), can result from muta

280 in KO (Ndp (KO) ) mouse, a model of familial exudative vitreoretinopathy (FEVR), developmental hypova

281 Participants with a diagnosis of familial exudative vitreoretinopathy (FEVR), Norrie disease, Coat

282 ornea, or a known family history of familial exudative vitreoretinopathy (FEVR), were also excluded.

283 n occurs in both Norrie disease and familial exudative vitreoretinopathy (FEVR).

284 are involved in the pathogenesis of familial exudative vitreoretinopathy (FEVR, MIM # 133780).

285 , ocular toxocariasis (n = 22; 4%), familial exudative vitreoretinopathy (FEVR; n = 18; 3%), rhegmato

286 ral retinal vasculitis (n = 4, 6%), familial exudative vitreoretinopathy (n = 3, 4%), and others (n =

287 Familial exudative vitreoretinopathy has a wide range of unrecogn

288 Given the risk of added vision loss posed by exudative vitreoretinopathy in patients with RP, a heigh

289 Screening genomic DNA samples from exudative vitreoretinopathy patients identifies three di

290 and median age at presentation of Coats-like exudative vitreoretinopathy was 18 years (range, 1-41 ye

291 agnosed with RP and demonstrating Coats-like exudative vitreoretinopathy were included.

292 is and at time of presentation of Coats-like exudative vitreoretinopathy, pedigree analysis, genetic

293 rs of signalling and are mutated in familial exudative vitreoretinopathy.

294 hemorrhage and a female infant with familial exudative vitreoretinopathy.

295 uently mutated in Norrie disease or familial exudative vitreoretinopathy.

296 sis, retinal hemangioblastomas, and familial exudative vitreoretinopathy.

297 leakage similar to the features of familial exudative vitreoretinopathy.

298 on of the microvascular density in eyes with exudative vs tractional (P = .002) and FTMH (P < .001) s

299 Progression to exudative 'wet' age-related macular degeneration (exAMD)

300 of central vision frequently occurs with the exudative (wet) form of AMD, as a result of the formatio